Geoffrey R. Oxnard, MD

Associate Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Geoffrey Oxnard is a thoracic oncologist at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School. The aims of Dr. Oxnard’s research are to develop clinical applications for cancer genotyping technologies to advance precision cancer care.

Dr. Oxnard has published extensively on sensitivity and resistance to EGFR kinase inhibitors in lung cancer with a focus on the clinical biology of the EGFR T790M mutation. More recently his research has focused on genomic analysis of plasma cell-free DNA as a diagnostic to assist in treatment planning, response monitoring, and cancer detection.

Dr. Oxnard received his BA in chemistry from Harvard University and his MD from the University of Chicago-Pritzker School of Medicine. He served his residency in internal medicine at Massachusetts General Hospital and completed his fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center, joining the Dana-Farber faculty in 2011.

Publications

  • Published 9/15/2026

    Dall'Olio FG, Zrafi W, Vasseur D, Garcia C, Beshiri K, Marinello A, Tagliamento M, Planchard D, Lassau N, Drubay D, Mamann A, Dawi L, Lawrance L, Lacroix L, Barlesi F, Gautheret D, Rouleau E, Deandreis D, Gasco A, Pasquina LW, Italiano A, Oxnard GR, Madison RW, Besse B. Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2026 Sep 15; 32(18):4113-4123. PMID: 42440365.

    Read at: PubMed

  • Published 8/25/2026

    Gerber DE, Wang Y, Langer CJ, Khullar OV, Kozono DE, Cornelius LA, Forde PM, Nwaneri MO, Neal JW, Talsania A, Leal TA, Patel M, Donthireddy KR, Waqar SN, Chaft JE, Govindan R, Sands JM, Malik S, Li T, Sun Z, Stinchcombe TE, Vokes EE, Mandrekar SJ, Oxnard GR, Carbone DP, Ramalingam SS. Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4512): a phase 3 trial. Lancet Respir Med. 2026 Nov; 14(11):972-982. PMID: 42641639.

    Read at: PubMed

  • Published 7/10/2026

    LoPiccolo J, Collins RL, Fields N, Nakagawa C, Taraszka K, Wang X, Su L, Koeller DR, Schwartz AL, Pollaci AC, Young SM, Williamson VG, Avila JA, Voligny E, Nguyen T, Pangilinan AJ, Erwin RM, Gitlitz BJ, Novello S, Oxnard GR, Chukwueke UN, Brastianos PK, Aizer AA, Hatabu MN, Florez N, Haigis KM, Van Allen EM, Nieva JJ, Garber JE, Christiani DC, Jänne PA, Gusev A. Germline determinants of risk and molecular subtype in young-onset lung cancer. medRxiv. 2026 Jul 10. PMID: 42465903.

    Read at: PubMed

  • Published 3/12/2026

    Murciano-Goroff YR, Hollebecque A, Heist RS, Cassier PA, Han JY, Kim SY, Sabari JK, Tosi D, Sacher A, Burns TF, Shimizu T, Reddy Ammakkanavar N, Spira A, Gomez-Roca C, Patnaik A, Cosman R, Bodor JN, Nagasaka M, You AX, McNeely SC, Peter R, Fink A, Chen A, Oxnard GR, Willard MD, Kuboki Y, Koyama T. Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study. Nat Commun. 2026 Mar 12; 17(1). PMID: 41820335.

    Read at: PubMed

  • Published 1/23/2026

    Ogino A, Vajdi A, Mu XJ, Mahadevan NR, Ngo K, Booker MA, Cejas P, Okoro JJ, Xu M, Springer BF, Eschle BK, Messier CM, Wang S, Syamala S, Tamen RM, Adeni AE, Chambers ES, Canadas I, Thai T, Christensen CL, Xu C, Lizotte PH, Oxnard GR, Watanabe H, Long HW, Gokhale PC, Paweletz CP, Sholl LM, Oser MG, Barbie DA, Tolstorukov MY, Jänne PA. EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy. JCI Insight. 2026 Jan 23; 11(2). PMID: 41574603.

    Read at: PubMed

View All 220 Publications:   View Full Profile in BUMC

Websites

Education

  • University of Chicago, MD
  • Harvard University, AB

View all profiles